AR amplification, alternative splicing of the AR, post-translational modifications to the AR, alteration of factors that control AR expression, or somatic gain-of-function mutations which are the hallmark of late-stage castration-resistant prostate cancer, are typically absent in localized cases of prostate cancer (35). This evidence concerns the gene AR and prostate carcinoma.